Tuis4AB • ETR
add
AbbVie Inc
Vorige sluiting
€173,78
Dagwisseling
€172,96 - €174,80
Jaarwisseling
€125,50 - €192,50
Markkapitalisasie
316,04 mjd USD
Gemiddelde volume
1,17 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NYSE
In die nuus
MarketBeat
20 uur gelede
AbbVie Inc. (NYSE:ABBV) Position Reduced by MetLife Investment Management
LLC
1,07%
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 14,46 mjd | 3,83% |
Bedryfskoste | 6,07 mjd | 21,67% |
Netto inkomste | 1,56 mjd | -12,20% |
Netto winsgrens | 10,80 | -15,43% |
Wins per aandeel | 3,00 | 1,69% |
EBITDA | 6,26 mjd | -8,02% |
Effektiewe belastingkoers | 24,95% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 7,28 mjd | -45,18% |
Totale bates | 143,42 mjd | 5,29% |
Totale aanspreeklikheid | 137,35 mjd | 10,68% |
Totale ekwiteit | 6,07 mjd | — |
Uitstaande aandele | 1,77 mjd | — |
Prys om te bespreek | 50,96 | — |
Opbrengs op bates | 7,33% | — |
Opbrengs op kapitaal | 13,48% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 1,56 mjd | -12,20% |
Kontant van bedrywe | 5,45 mjd | -28,08% |
Kontant van beleggings | -8,26 mjd | -2 137,40% |
Kontant van finansiering | -3,07 mjd | -15,45% |
Netto kontantverandering | -5,87 mjd | -229,70% |
Beskikbare kontantvloei | 5,50 mjd | -26,01% |
Meer oor
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira, administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
It developed Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases. Its other major products include Botox, Imbruvica to treat cancer, Rinvoq to treat arthritis, Venclexta to treat leukemia and lymphoma, Vraylar to treat schizophrenia and bipolar disorder, and Mavyret to treat Hepatitis C. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.
In 2023, Humira began facing competition from a biosimilar developed by Amgen. Wikipedia
Gestig
01 Jan. 2013
Webwerf
Werknemers
50 000
